Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12638740 | 1.00 | TSHR (0.33) | TSHRALDH1A1 | |
| SCHEMBL26659547 | 1.00 | TSHR (0.33) | TSHRALDH1A1 | |
| SCHEMBL30999485 | 0.81 | ALDH1A1 (0.32) | TSHRALDH1A1 | |
| SCHEMBL4180706 | 0.78 | PGD (0.33) | — | |
| SCHEMBL4180699 | 0.78 | PGD (0.33) | — | |
| SCHEMBL6484089 | 0.78 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL6496531 | 0.78 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL4455207 | 0.78 | PGD (0.33) | — | |
| SCHEMBL9805186 | 0.77 | — | — | |
| SCHEMBL21234118 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270209-A1 | LRRK2 INHIBITORS | INTERLINE THERAPEUTICS, INC. | 2025-08-28 | — | — | US | disclosed |
| EP-4522616-A1 | LRRK2 INHIBITORS | Interline Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20250066356-A1 | LRRK2 INHIBITORS | INTERLINE THERAPEUTICS, INC. | 2025-02-27 | — | — | US | disclosed |
| WO-2023220247-A1 | LRRK2 INHIBITORS | INTERLINE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2003051862-A1 | PROCESS FOR THE PREPARATION OF PYRANONE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066356-A1 | LRRK2 INHIBITORS | LRRK2, PARK7, PINK1 | TSHR 4664/4885ALDH1A1 2142/4885 |
| US-20250270209-A1 | LRRK2 INHIBITORS | LRRK2, PARK7, PINK1 | TSHR 4664/4885ALDH1A1 2142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.